Genomes and Genes
Summary: Conditions in which the bone marrow shows qualitative and quantitative changes suggestive of a preleukemic process, but having a chronic course that does not necessarily terminate as acute leukemia.
Publications284 found, 100 shown here
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesJames W Vardiman
Department of Pathology, University of Chicago, IL, USA
Blood 114:937-51. 2009....
- Mutation in TET2 in myeloid cancersFrancois Delhommeau
INSERM U790, Institut Gustave Roussy, Villejuif, France
N Engl J Med 360:2289-301. 2009The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined.
- Frequent pathway mutations of splicing machinery in myelodysplasiaKenichi Yoshida
Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
Nature 478:64-9. 2011b>Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, ..
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux
Hopital Avicenne, Universite Paris XIII, Bobigny, France
Lancet Oncol 10:223-32. 2009Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage...
- Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromesGorica Nikoloski
Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
Nat Genet 42:665-7. 2010In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36...
- Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotypeDaniel T Starczynowski
British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada
Nat Med 16:49-58. 2010..Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q- syndrome...
- Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesGuillermo Garcia-Manero
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 111:1060-6. 2008..Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible...
- Somatic SF3B1 mutation in myelodysplasia with ring sideroblastsE Papaemmanuil
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
N Engl J Med 365:1384-95. 2011b>Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies.
- Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1794-803. 2006Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy...
- Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer
Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
Br J Haematol 145:788-800. 2009The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal haematological diseases characterized by ineffective haematopoiesis and predisposition to acute myeloid leukaemia (AML). The pathophysiology of MDSs remains unclear...
- Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromesW T Bellamy
Department of Pathology, and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Blood 97:1427-34. 2001....
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:2302-8. 2007..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromesM J Walter
Department of Internal Medicine, Division of Oncology, Washington University, St Louis, MO 63110, USA
Leukemia 25:1153-8. 2011Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown...
- A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Clin Cancer Res 12:4628-35. 2006..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
- Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)I Kotsianidis
Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
Leukemia 23:510-8. 2009..In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis ..
- Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsSteven D Gore
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
Cancer Res 66:6361-9. 2006..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLYing Jiang
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
Blood 113:1315-25. 2009b>Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML)...
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylationMaria E Figueroa
Department of Medicine Hematology Oncology Division, Weill Cornell Medical College, New York, NY 10065, USA
Blood 114:3448-58. 2009..Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors...
- International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview reportJanet D Rowley
Department of Medicine, University of Chicago, Chicago, Illinois, USA
Genes Chromosomes Cancer 33:331-45. 2002
- CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)Shahram Y Kordasti
Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
Blood 110:847-50. 2007..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
- Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangementsIdoya Lahortiga
Department of Genetics, University of Navarra, Pamplona, Spain
Genes Chromosomes Cancer 40:179-89. 2004..Our data suggest that a unique mechanism is not likely to be involved in 3q21q26 rearrangements...
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosisFelicitas Thol
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
Haematologica 95:1668-74. 2010b>Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with a high propensity to transform into acute myeloid leukemia...
- Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemiaJ Pedersen-Bjergaard
The Chromosome Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Juliane Marie Center, Copenhagen, Denmark
Leukemia 20:1943-9. 2006....
- DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromesElizabeth A Griffiths
Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins Hospital, Baltimore, MD 21231, USA
Semin Hematol 45:23-30. 2008..Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease...
- Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesisTimothy A Graubert
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, United States of America
PLoS ONE 4:e4583. 2009..2 are among the most common recurring cytogenetic abnormalities detectable in myelodysplastic syndromes (MDS). Prior genomic studies have suggested that haploinsufficiency of multiple 5q31...
- Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapyDawn Hershman
Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
J Natl Cancer Inst 99:196-205. 2007..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
- Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemiaJens Pedersen-Bjergaard
Cytogenetic Laboratory, Section 4052, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
Blood 99:1909-12. 2002..Recent research suggests that these 2 general types of t-AML can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics...
- A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: Obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomesRuth N MacKinnon
Victorian Cancer Cytogenetics Service, St Vincent s Hospital Melbourne, Australia
Genes Chromosomes Cancer 46:27-36. 2007The dic(17;20) is a recurrent unbalanced translocation occurring rarely in myelodysplastic syndromes and acute myeloid leukemia...
- Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaAmanda F Cashen
Washington University School of Medicine, St Louis, MO, USA
J Clin Oncol 28:556-61. 2010..We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML...
- Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromesTimothy A Graubert
Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
Nat Genet 44:53-7. 2012b>Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML)...
- Molecular bases of myelodysplastic syndromes: lessons from animal modelsYukiko Komeno
Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
J Cell Physiol 219:529-34. 2009..In this review, we summarize the animal models of MDS and discuss the molecular bases of MDS as well as those of leukemia and myeloproliferative disorders (MPD). J. Cell. Physiol. 219: 529-534, 2009. (c) 2009 Wiley-Liss, Inc...
- Cytogenetic features in myelodysplastic syndromesDetlef Haase
Department of Hematology and Oncology, Georg August University, Robert Koch Str 40, 37075, Gottingen, Germany
Ann Hematol 87:515-26. 2008b>Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases characterized by profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features...
- Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study GroupKatharina Götze
III Medizinische Klinik, Technische Universitat Munchen, Ismaningerstrasse 15, Munich, Germany
Ann Hematol 89:841-50. 2010b>Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML)...
- Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic SyndromesDominik Beck
Bioengineering and Bioinformatics Program, Department of Pathology, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, TX, 77030, USA
BMC Med Genomics 4:19. 2011b>Myelodysplastic Syndromes (MDSS) are pre-leukemic disorders with increasing incident rates worldwide, but very limited treatment options...
- Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for ReseMichael Lubbert
Albert Ludwigs University, Freiburg, Germany
J Clin Oncol 29:1987-96. 2011..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy...
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson
Service d Hématologie Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 13, Bobigny, France
Leukemia 25:1147-52. 2011..Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype...
- TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progressionMartin Jadersten
Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
J Clin Oncol 29:1971-9. 2011To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression.
- Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaGuillermo Garcia-Manero
University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, Houston, TX 77025, USA
J Clin Oncol 29:2521-7. 2011..safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman
Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Cancer 117:2697-702. 2011....
- NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)Daniella M B Kerbauy
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA, 98109-1024, USA
Blood 106:3917-25. 2005..However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-kappaB, may have considerable therapeutic activity...
- Clinical effect of point mutations in myelodysplastic syndromesRafael Bejar
Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
N Engl J Med 364:2496-506. 2011b>Myelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia...
- Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prebet
Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
J Clin Oncol 29:3322-7. 2011..The outcome of these patients has not yet been described...
- Unraveling the molecular pathophysiology of myelodysplastic syndromesRafael Bejar
Brigham and Women s Hospital, Karp Research Building, CHRB 05 211, 1 Blackfan Cir, Boston, MA 02115, USA
J Clin Oncol 29:504-15. 2011Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of progression to acute myeloid leukemia...
- Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini
Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Eur J Haematol 85:130-8. 2010..We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them...
- Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromesAsaka Kondo
Division of Hematology, Department of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
Blood 116:1124-31. 2010During disease progression in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells become less efficient via an unknown mechanism...
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinionPierre Fenaux
Hopital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France
Leuk Res 34:1410-6. 2010..in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals...
- Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantationR Zeiser
Department of Hematology and Oncology, Freiburg University Medical Center, Albert-Ludwigs University, Freiburg, Germany
Leukemia 19:814-21. 2005....
- Current and future management options for myelodysplastic syndromesJeffrey Bryan
Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Drugs 70:1381-94. 2010The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease...
- Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian
Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Blood 116:3163-70. 2010..efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy...
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson
Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris, Paris, France
Blood 117:403-11. 2011..In conclusion, routine tests can identify subgroups of patients with distinct prognosis with AZA treatment...
- Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour
Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia
Crit Rev Oncol Hematol 76:218-27. 2010..Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥ 75 years with good performance status and higher-risk MDS...
- Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a reviewPaolo Bernasconi
Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Br J Haematol 142:695-708. 2008The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both hematopoietic stem cell disorders...
- Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regionsNathalie Douet-Guilbert
Laboratoire d Histologie, Embryologie et Cytogenetique, Faculte de Medecine et des Sciences de la Sante, Universite de Bretagne Occidentale, Brest, France
Ann Hematol 87:537-44. 2008Deletion of the long arm of chromosome 20 is a recurrent abnormality observed in myelodysplastic syndromes (MDS) and in Philadelphia-chromosome-negative myeloproliferative disorders (MPD)...
- Risk factors of myelodysplastic syndromes: a case-control studyS S Strom
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Leukemia 19:1912-8. 2005Little is known about the etiology of myelodysplastic syndromes (MDS)...
- Occupational exposures and haematological malignancies: overview on human recent dataAlexis Descatha
Unité de pathologie professionnelle et de santé au travail, Hôpital R Poincaré, AP HP 92380 Garches, France
Cancer Causes Control 16:939-53. 2005..Occupational causes of haematological malignancies are relatively uncommon, under-studied and under-identified. They are also often unrecognized by clinicians. This review summarizes the principal epidemiologic studies on this topic...
- Epidemiology of myelodysplastic syndromesSara S Strom
Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
Semin Hematol 45:8-13. 2008b>Myelodysplastic syndromes (MDS) are one of the most common hematological conditions among the elderly. Differences in disease classification and diagnosis have made population-based studies an arduous endeavor...
- Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshopMette K Andersen
Cytogenetic Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
Genes Chromosomes Cancer 33:395-400. 2002..Response rates to intensive chemotherapy in this study were comparable to those of de novo disease...
- High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survivalDaniel T Starczynowski
Department of Medical Biophysics, British Columbia Cancer Agency, Vancouver, Canada
Blood 112:3412-24. 2008b>Myelodysplastic syndromes (MDSs) pose an important diagnostic and treatment challenge because of the genetic heterogeneity and poorly understood biology of the disease...
- Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocationMarina Bousquet
Institut National de Santé et de Recherche Médicale, U563, Centre de Physiopathologie de Toulouse Purpan, 31300 Toulouse, France
J Exp Med 205:2499-506. 2008Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) involve oncogenes that are either up-regulated or form part of new chimeric genes...
- Safety and efficacy of azacitidine in myelodysplastic syndromesCarlos E Vigil
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Drug Des Devel Ther 4:221-9. 2010..The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed...
- A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndromeAlzbeta Vasikova
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Leuk Res 34:1566-72. 2010..The results suggest that increased cell proliferation and resistance to apoptosis together with a loss of cell cycle control, damaged DNA repair and altered immune response may play an important role in malignant clone expansion in MDS...
- Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator geneA Minelli
Biologia Generale e Genetica Medica, , C.P. 217, I 27100, Pavia, Italy
Cancer Genet Cytogenet 124:147-51. 2001..We postulate that, in fact, an inherited mutation in any of a group of mutator genes causes familial monosomy 7 also in the absence of a recognized mendelian disease, and that marrow chromosome 7 anomalies, in turn, lead to MDS/AML...
- NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemiaYing-Wei Lin
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
Blood 106:287-95. 2005The myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem-cell disorders characterized by ineffective hematopoiesis and dysplasia...
- Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding riskDebra A Patt
Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:3871-6. 2007..The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women...
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaSteven D Gore
The Johns Hopkins Oncology Center, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Clin Cancer Res 8:963-70. 2002..Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition...
- Consensus statement on iron overload in myelodysplastic syndromesJohn M Bennett
The Myelodysplastic Syndromes Foundation, Crosswicks, New Jersey, USA
Am J Hematol 83:858-61. 2008In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25)...
- Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga
Centre Oscar Lambret, Lille, France
J Clin Oncol 23:4179-91. 2005..Increased risk of secondary leukemia must be considered when assessing the potential benefit to risk ratio of higher than standard doses...
- A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancersAnneclaire J De Roos
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Department of Epidemiology, University of Washington, Seattle, WA 98109 1024, USA
Cancer Causes Control 18:1199-208. 2007b>Myelodysplastic syndromes (MDS) following treatment with chemotherapy or irradiation are termed 'secondary' MDS...
- Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classificationsIrene Lorand-Metze
Department of Internal Medicine, Hemocentro State University of Campinas, PO Box 6198, BR 13081 970, Campinas, SP, Brazil
Leuk Res 28:587-94. 2004The WHO classification for myelodysplastic syndromes (MDS) has introduced new categories with prognostic relevance...
- Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study GroupAndreas Josting
First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
J Clin Oncol 21:3440-6. 2003..To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin's disease (HD)...
- Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann
Heinrich Heine University, Dusseldorf, Germany
Leuk Res 34:1143-50. 2010The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve...
- Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family membersAruna Padmanabhan
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
Leuk Res 32:1820-3. 2008..and radiation therapy for breast cancer are associated with therapy-related acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS), but little is known about additional risk factors...
- In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndromeEugenia Flores-Figueroa
Oncological Research Unit, Oncology Hospital, National Medical Center, IMSS, Av. Cuauhtemoc 330, Mexico DF 06720, Mexico
Leuk Res 26:677-86. 2002..indicating that there are alterations in the function of microenvironment (adherent) cell layers from myelodysplastic syndromes (MDS) marrow...
- Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defectH Chen
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
Lancet 347:295-7. 1996..to various cytotoxic and genotoxic agents, including those associated with increased risk of the myelodysplastic syndromes (MDS)...
- Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?Zuzana Sieglova
Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague, Czech Republic
Leuk Res 28:1013-21. 2004Telomere length was evaluated by terminal repeat fragment method (TRF) in 50 patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) arising from MDS and in 21 patients with untreated primary AML to ascertain, ..
- The role of apoptosis in the pathogenesis of the myelodysplastic syndromesJ E Parker
The Department of Haematological Medicine, Guy's, King's, Thomas' School of Medicine, London, UK
Int J Hematol 73:416-28. 2001The paradoxical occurrence of peripheral cytopenias despite a normo/hypercellular marrow in myelodysplastic syndromes (MDS) has been attributed to excessive intramedullary hematopoietic cell apoptosis...
- Impact of iron overload in myelodysplastic syndromesPierre Fenaux
Groupe Francophone des Myélodysplasies, France
Blood Rev 23:S15-9. 2009Anaemia is prevalent in patients with myelodysplastic syndromes (MDS), and most patients with MDS receive regular red blood cell transfusions, which can lead to iron overload...
- Cause of death in patients with lower-risk myelodysplastic syndromeFarshid Dayyani
Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:2174-9. 2010..The cause of death (COD) of these patients is not well understood. Identifying the COD could help to guide early therapy decisions...
- Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndromeM Iwai
Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan
Leukemia 19:1367-75. 2005..These results suggested that FHIT methylation was accumulated through the disease progression of MDS and AML, and the role of the FHIT gene as a tumor suppressor seemed different in AML and MDS...
- Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B studyCheri E Klein
Department of Biopharmaceutical Sciences, The University of Illinois at Chicago, 833 South Wood Street (MC 865, Chicago, IL 60612, USA
Cancer Chemother Pharmacol 57:199-206. 2006..medication adherence, pharmacokinetics and exposure versus response relationships in patients with myelodysplastic syndromes (MDS). METHODS: Ninety adult patients with MDS received oral topotecan (1...
- Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellstrom-Lindberg
Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
Blood Rev 24:83-90. 2010The pathogenesis of myelodysplastic syndromes involves a pattern of genetic, epigenetic, and immune-mediated mechanisms but little is known about what causes the specific disease features and promotes disease progression in the ..
- Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disordersIrene Lorand-Metze
Department of Internal Medicine, Hemocentro, State University of Campinas, P O Box 6198, BR 13081 970 Campinas, Sao Paulo, Brazil
Leuk Res 31:147-55. 2007The diagnosis of myelodysplastic syndromes (MDS) is based on peripheral cytopenias, bone marrow (BM) morphology and karyotyping. This may be difficult in cases with few dysplastic elements in BM and a normal karyotype...
- Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemiaH Kurotaki
Department of Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
Acta Haematol 102:115-23. 2000....
- Epidemiological characteristics of myelodysplastic syndrome in a well-defined French populationM Maynadie
Registre des Hémopathies Malignes de Côte d Or, Equipe associée INSERM DGS, Dijon, France
Br J Cancer 74:288-90. 1996Data on myelodysplastic syndromes (MDS) are seldom collected by cancer registries and unbiased findings from population-based studies remain rare...
- Myelodysplastic syndromes: From pathogenesis and prognosis to treatmentPierre Fenaux
Service d Hematoilogie, Clinicique Paris XIII University, Avicenne Hospital, France
Semin Hematol 41:6-12. 2004b>Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML)...
- Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromesL Ma
Laboratory for Experimental Hematology, University of Leuven, Leuven, Belgium
Leukemia 18:1451-6. 2004..lymphoid precursor dendritic cell (pDC) counts were determined in peripheral blood from 22 patients with myelodysplastic syndromes (MDS) by a single-platform flow cytometric protocol...
- Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemiaM F Johan
Br J Haematol 124:843-4. 2004
- Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced diseaseManuel Aivado
Proteomics Core and Department of Medical Oncology, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 104:1307-12. 2007b>Myelodysplastic syndromes (MDS) are among the most frequent hematologic malignancies. Patients have a short survival and often progress to acute myeloid leukemia...
- Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United StatesThomas F Goss
Covance Market Access Services Inc, Gaithersburg, MD 20878, USA
Cancer Control 13:17-25. 2006Lenalidomide has been approved for the treatment of transfusion-dependent low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities...
- The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network GuidelinesPeter L Greenberg
Stanford University Cancer Center, Stanford, California 94305 5821, USA
J Natl Compr Canc Netw 6:942-53. 2008Guidelines for management of patients with myelodysplastic syndromes (MDS) have been generated by the National Comprehensive Cancer Network (NCCN) Myelodysplastic Syndromes Panel...
- Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndromeA M Jankowska
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
Leukemia 22:551-8. 2008In myelodysplastic syndromes (MDS) increased chromosomal breaks point toward defects in DNA repair machinery including base excision repair (BER) pathway involved in handling of oxidative DNA damage...
- Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromesVirginia M Klimek
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:826-32. 2008..study was to evaluate the toxicity, pharmacokinetic profile, and selected pharmacodynamic properties of the histone deacetylase inhibitor depsipeptide in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).
- Treatment strategies in myelodysplastic syndromesEhab Atallah
Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Cancer Invest 26:208-16. 2008b>Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS...
- Current status of epigenetic treatment in myelodysplastic syndromesAndrea Kuendgen
Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
Ann Hematol 87:601-11. 2008..The first treatment approved by the Food and Drug Administration for the treatment of myelodysplastic syndromes (MDS) was the DNMT-inhibitor 5-azacytidine...
- Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?A Cortelezzi
Servizio Autonomo di Ematologia Diagnostica, Ospedale Maggiore, IRCCS, Milano, Italy
Hematol J 1:153-8. 2000Iron overload is usually observed in patients (even untransfused) with myelodysplastic syndromes (MDS), and contributes towards the generation of low molecular weight iron complexes or non-transferrin-bound iron (NTBI), which in turn ..
- 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshopClara D Bloomfield
Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
Genes Chromosomes Cancer 33:362-78. 2002..We conclude that among t-MDS/t-AL patients with balanced aberrations, 11q23 translocations are an independent adverse risk factor. Although BMT is the current therapy of choice, new treatment is required...
- Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromesW K Hofmann
Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
Leuk Res 25:855-8. 2001To understand the underlying mechanisms in myelodysplastic syndromes (MDS) by identifying target tumor suppressor genes, we performed a detailed deletional mapping of the short arm of chromosome 1 in 38 paired samples of bone marrow and ..
- Changing the treatment paradigm in myelodysplastic syndromesGhulam J Mufti
Kings College London and Kings College Hospital, Department of Haematological Medicine, London SE5 9RS UK
Cancer Control 15:14-28. 2008..Timing of available therapies, including stem cell transplantation, should be incorporated into the new treatment paradigm, with end goals of prolonging survival and optimizing patient outcomes...
- Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10)Hui-Hua Hsiao
The First Department of Internal Medicine; Department of Internal Medicine, Kaohsiung Medical University Hospital, 100, Tz-You 1st Road, Kaohsiung 807, Taiwan
Cancer Genet Cytogenet 165:161-6. 2006We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34...
- A prognostic score for patients with lower risk myelodysplastic syndromeG Garcia-Manero
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Leukemia 22:538-43. 2008Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention...
- High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberrationK Paulsson
Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
Leukemia 20:840-6. 2006..sole chromosome aberration is the most common numerical abnormality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), little is known about its pathogenetic effects...
- NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALINGDAVID LARGAESPADA; Fiscal Year: 2002DESCRIPTION: (adapted from the investigator's abstract) Treatment of childhood myelodysplastic syndromes (MDS) as well as chronic and acute myeloid leukemia (CML and AML) remains disappointing compared with well known advances in the ..
- Molecular Pathogenesis of MDS and CMMLJaroslaw P Maciejewski; Fiscal Year: 2010..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
- Molecular Pathogenesis of MDS and CMMLJaroslaw P Maciejewski; Fiscal Year: 2011..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
- Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)Pearlie K Epling Burnette; Fiscal Year: 2009b>Myelodysplastic syndromes (MDS) are characterized by incompetent hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
- A mouse model of myelodysplastic syndrome progression and leukemic stem cellsYupo Ma; Fiscal Year: 2009..Expiration Date: 04/30/2008 Principal Investigator/Program Director (Last, first, middle): Ma, Yupo Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual ..
- MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORSEdward Newman; Fiscal Year: 2001..in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes. After incorporation into DNA, DAC inhibits the enzyme DNA (cytosine-5)-methyltransferase (MT'ase)...
- New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)Elihu Estey; Fiscal Year: 2007The incidence of myelodysplastic syndromes (MDS) is likely to increase as the U.S. population ages. Nonetheless, there are no satisfactory treatments...
- Cyclin E Regulation in Normal and Neoplastic HematopoiesisALEXANDER C MINELLA; Fiscal Year: 2010..These features are characteristics of hematopoietic cells of patients with early-stage myelodysplastic syndromes (MDS)...
- FMS TRANSFORMATION/CSF-1 RECEPTOR SIGNAL TRANSDUCTIONMartine Roussel; Fiscal Year: 1993..human FMS might contribute to the etiology of myeloid proliferative disorders, including leukemias and myelodysplastic syndromes, but no bona fide activating mutations at codon 301 have thus far been identified...
- The Role of the APC Tumor Suppressor Gene in Hematopoiesis and LeukemogenesisZhijian Qian; Fiscal Year: 2010..The myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells (HSCs), characterized by ineffective ..
- Targeted Therapy of Lyn in Myelodysplastic SyndromeSETH JOEL COREY; Fiscal Year: 2010b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
- Targeted Therapy of Lyn in Myelodysplastic SyndromeSeth Corey; Fiscal Year: 2006b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
- Targeted Therapy of Lyn in Myelodysplastic SyndromeSeth Corey; Fiscal Year: 2007b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
- Clinical Hematology Research Career Development Program (K12)Ellis Neufeld; Fiscal Year: 2007..and thalassemia; hemophilia and other hemostatic disorders; venous thromboembolism and thrombophilias; myelodysplastic syndromes and myeloproliferative disorders; transfusion medicine, including unique aspects of pediatric ..
- Contribution of the vascular niche to the hematopoietic reconstitution.Shahin Rafii; Fiscal Year: 2010..and HSC self-renewal will offer new strategies to treat BM failure states, including aplastic anemia, myelodysplastic syndromes and accelerate BM reconstitution after chemotherapy, irradiation and transplantation...
- Modeling Multi-step Leukemogenesis in Nf1 and Kras Mutant MiceJENNIFER LAUCHLE; Fiscal Year: 2007..In contrast, myelodysplastic syndromes (MDSs) are usually associated with low blood cell counts and aberrant bone marrow morphology, while ..
- Bone Marrow Failure Clinical Research CenterJaroslaw Maciejewski; Fiscal Year: 2006..cytopenias including large granular lymphocyte leukemia and pure red cell aplasia, and various myelodysplastic syndromes. This application presents a multi-targeted approach to improving the medical therapy for IBMFS&C ..